A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head & Neck Squamous Cell Carcinoma (HNSCC)

Description

The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.

Conditions

Head and Neck Squamous Cell Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.

TEMPUS PHOENIX HNSCC STUDY: a Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head & Neck Squamous Cell Carcinoma (HNSCC)

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head & Neck Squamous Cell Carcinoma (HNSCC)

Condition
Head and Neck Squamous Cell Carcinoma
Intervention / Treatment

-

Contacts and Locations

Duarte

City of Hope, Duarte, California, United States, 91010

Los Angeles

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States, 90033

Decatur

Cancer Care Specialists of Illinois, Decatur, Illinois, United States, 62526

Peoria

Illinois Cancer Care, Peoria, Illinois, United States, 61615

Saint Louis

Washington University in St. Louis, Saint Louis, Missouri, United States, 63130

Springfield

Oncology Hematology Associates, Springfield, Missouri, United States, 65807

New York

Mount Sinai Hospital, New York, New York, United States, 10029

York

Cancer Care Associates of York, York, Pennsylvania, United States, 17403

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ≥18 years of age
  • * Willing and able to provide informed consent
  • * Histologically- or cytologically-confirmed metastatic or unresectable, recurrent HNSCC unsuitable for local therapies
  • * Intended for first line anti-PD1 or PDL1 monotherapy or combination therapy
  • * Must submit tumor tissue sample representative of current disease per laboratory manual
  • * Non-squamous histologies (eg, nasopharynx or salivary gland)
  • * Relapse or recurrence within 6 months of first line chemotherapy and / or chemoradiotherapy
  • * Tumors that are PD-L1 negative (CPS \<1)
  • * Clinical evidence of an active second invasive malignancy within \<2 years of enrollment with the exception of stable prostate cancer on watchful waiting, in situ cervical cancer, in situ breast carcinoma or localized non-melanoma skin cancers
  • * Unable to comply with study procedures (i.e., not willing or able to have additional blood samples collected)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Tempus AI,

Virginia Rhodes, MD, STUDY_DIRECTOR, Tempus AI, Inc.

Study Record Dates

2028-03-01